Program
BMS-986525
A development code.
Its studies are mostly in Small Cell Lung Carcinoma, led by Bristol-Myers Squibb.
Furthest: phase 2, since Jan 6, 20261 company-led study, 1 open or runningNext primary completion: Apr 23, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 11 open or running | phase 2since Jan 6, 2026 | Jan 6, 2026 | Apr 23, 2029phase 2 · NCT07325136 |
- Named in Bristol-Myers Squibb’s own pipeline as
BMS-986525
, phase 1, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 6, 2026First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT07325136 · 240 planned · United States, China, Italy and more
Ahead
- Apr 23, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07325136
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07325136Small Cell Lung Carcinoma · United States, China, Italy and more | 2 | Recruiting | Apr 23, 2029 | 240 |
How it is read
Names in the registry
- “BMS-986525”, 1 entry
Codes read as this program: BMS986525.
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.